Genfit among the biggest decliners in the SBF 120, but up 21% over the week
The Lille-based biotech specializing in liver and metabolic diseases dips mid-session, in a Paris market that is rising. It nonetheless holds most of the rebound begun at the end of October, after a very difficult quarter.
An intraday pullback that does not erase the sharp weekly rebound
The stock falls 3.13% to €10.52, while the CAC 40 gains 0.46% and the SBF 120 gains 0.4%. It thus ranks among the biggest decliners in the latter index. This decline follows a 21.34% rise over the week, so it only trims part of the recent gain.
Over three months, the loss remains heavy at 28.24%, and the weekly gain offsets it only in part.
The price falls back below the MM50, at €10.86, a gap of 3.13%, while remaining well above the MM20 (gap of 14.72%) and the MM200 (gap of 5.73%). It trades below the resistance at €11.46, which the weekly rebound did not break through.
The AASLD congress, the company's latest published news
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
On Monday, November 2, Genfit detailed its program of activities organized on the sidelines of the AASLD The Liver Meeting 2026 congress.
The company presents two areas of focus: its therapeutic approach in acute-on-chronic liver failure (ACLF) and its diagnostic activity for metabolic dysfunction-associated steatohepatitis (MASH). This program dedicated to ACLF and MASH diagnosis extends the positioning of the Genfit stock in liver diseases.
The next financial deadline is the publication of third-quarter 2026 revenue, scheduled for November 5.
SectorPharmacie et biotechnologies›Biotechnologies
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 9M 2026
Key reported figures
Revenue: 36,4 millions d'euros
Quarterly revenue: 36,4 millions d'euros
Revenue growth: -7,1 %
Guidance from the release
« conforte GENFIT dans son anticipation de la réception possible d'un nouveau paiement d'étape commercial » ; « permettent un financement des activités au-delà de fin 2028 »
Risks mentioned
Dépendance envers Ipsen pour la majorité des revenus (redevances sur ventes d'Iqirvo), qui représente 99,7% des revenus de redevances
Paiements d'étape commerciaux futurs soumis à conditions réglementaires et commerciales incertaines
Besoin de financement au-delà de 2028 dépendant de la croissance des ventes d'élafibranor et de l'adoption commerciale des technologies NIS™
Opportunities identified
Croissance des ventes d'Iqirvo auprès d'Ipsen (188% YoY sur redevances) avec pic de ventes révisé à 1 milliard d'euros
Medicare a approuvé le remboursement du test NASHnext® en août 2026, ouvrant un marché potentiel estimé à plus de 1,5 milliard de dollars à horizon 2033
Lancement de trois essais cliniques de Phase 2 (ACLF, CCA) avec résultats attendus en 2027
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
